Loading company…
Los Angeles-based Ritter Pharmaceuticals develops therapeutic products for gastrointestinal diseases, including RP-G28 for lactose intolerance.
Founded in 2004 and based in California, US, Ritter Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal diseases. Its RP-G28, described as an FDA-approved treatment for lactose intolerance, is its flagship product. The company also researches treatments for immuno-oncology, metabolic and liver diseases. Its stage is listed as Series C.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in